Cyclic Compounds Inhibiting TLR4 Signaling for Neuropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, inflammatory diseases, chemotherapy-induced peripheral neuropathy, chemotherapy-induced neuropathic pain, liver injury, and ischemia-reperfusion injury lack effective TLR4 signaling inhibitors.
Innovation Solution
Development of specific cyclic compounds, such as those represented by formula (I), which act as TLR4 signaling inhibitors, offering therapeutic potential for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for autoimmune diseases and inflammatory diseases, then current therapeutic approaches are maintained, but effective TLR4 signaling inhibition is not achieved
Solution Approach 1:
The patent applies parameter changes by systematically varying the chemical structure of cyclic compounds (formula I) including different ring sizes (5-7 membered), substituent positions, and functional groups to optimize TLR4 signaling inhibition. This structural parameter optimization enables the compounds to effectively inhibit TLR4 signaling across multiple disease types including autoimmune diseases, inflammatory diseases, chemotherapy-induced peripheral neuropathy, and ischemia-reperfusion injury, thereby achieving both high reliability and broad adaptability
2Adaptability or versatility
If TLR4 signaling inhibitors are developed for multiple disease types, then therapeutic versatility is improved, but the complexity of compound development increases
Solution Approach 1:
The patent implements universality by designing cyclic compounds with a core structural framework (formula I) that can universally inhibit TLR4 signaling across multiple disease indications. The compounds demonstrate broad therapeutic versatility by effectively treating autoimmune diseases, inflammatory diseases, chemotherapy-induced peripheral neuropathy, chemotherapy-induced neuropathic pain, liver injury, and ischemia-reperfusion injury, all through the same mechanism of TLR4 signal inhibition without requiring disease-specific modifications
Solution Approach 2:
The patent manages complexity through systematic parameter changes in the cyclic compound structure, where variations in ring size (5-7 membered), substituent types, and positional isomers are explored to optimize activity. This structured approach to parameter variation allows for the development of multiple effective compounds with manageable structural complexity while maintaining broad therapeutic applicability
Data Source
AI summary
The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).